Baxter International

Baxter International Inc. develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions.  The company operates through three segments: BioScience, Medication Delivery, and Renal. Patients and providers rely on Baxter for lifesaving renal and medical products, including intravenous (IV) solutions, systems and administrative sets, IV infusion parenteral nutrition, perioperative care, pharmacy devices and software, acute renal care, and home and in-center dialysis.

Company Growth (employees)
Type
Public
HQ
Deerfield, US
Founded
1931
Size (employees)
48,000 (est)
Website
baxter.com
Baxter International was founded in 1931 and is headquartered in Deerfield, US

Key People at Baxter International

José Almeida

José Almeida

Chairman, President and Chief Executive Officer
James K. Saccaro

James K. Saccaro

VP & CFO
Paul E. Martin

Paul E. Martin

VP & CIO
Jeanne K. Mason

Jeanne K. Mason

VP of HR
Andrew Frye

Andrew Frye

Senior Vice President and President, APAC

Baxter International Office Locations

Baxter International has offices in Deerfield, Ho Chi Minh City, Minneapolis, Newbury and in 35 other locations
Deerfield, US (HQ)
One Baxter Parkway
Show all (39)

Baxter International Data and Metrics

Baxter International Financial Metrics

Baxter International's revenue was reported to be $10.2 b in FY, 2016 which is a 2% increase from the previous period.
USD

Revenue (FY, 2016)

10.2 b

Revenue growth (FY, 2015 - FY, 2016), %

2%

Gross profit (FY, 2016)

4.1 b

Gross profit margin (FY, 2016), %

40%

Net income (FY, 2016)

5 b

EBIT (FY, 2016)

724 m

Market capitalization (25-Jul-2017)

34.2 b

Cash (31-Dec-2016)

2.8 b

EV

34.2 b
Baxter International's current market capitalization is $34.2 b.
USDFY, 2015FY, 2016

Revenue

10 b10.2 b

Revenue growth, %

(40%)2%

Cost of goods sold

5.8 b6.1 b

Gross profit

4.1 b4.1 b

Gross profit Margin, %

42%40%

EBIT

449 m724 m

EBIT margin, %

5%7%

Pre tax profit

428 m5 b

Net Income

968 m5 b
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

2.7 b2.9 b2.2 b2.8 b

Inventories

3.5 b3.6 b1.6 b1.4 b

Current Assets

10 b10.4 b11.8 b6.6 b

PP&E

7.8 b8.7 b4.4 b4.3 b

Goodwill

4.2 b3.9 b2.7 b2.6 b

Total Assets

25.9 b25.9 b21 b15.5 b

Total Debt

8.3 b8.5 b5.7 b2.8 b

Current Liabilities

5.9 b6 b5.8 b2.7 b

Retained Earnings

11.9 b13.2 b9.7 b14.2 b

Total Equity

8.5 b8.2 b8.9 b8.3 b

Debt to Equity Ratio

1 x1 x0.6 x0.3 x

Debt to Assets Ratio

0.3 x0.3 x0.3 x0.2 x

Financial Leverage

3 x3.2 x2.4 x1.9 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

2 b2.5 b968 m5 b

Inventories

(311 m)(439 m)1.6 b80 m

Cash From Operating Activities

2.2 b3.2 b1.8 b1.7 b

Capital Expenditures

(1.5 b)(1.9 b)(911)(719 m)

Cash From Investing Activities

5.4 b(1.5 b)(1.8 b)(715 m)

Cash From Financing Activities

1.6 b(1.4 b)(481 m)(324 m)

Interest Paid

200 m208 m178 m99 m

Income Taxes Paid

648 m726 m466 m500 m

Free Cash Flow

3.7 b5.1 b1.8 b2.4 b
USDY, 2016

EV/EBIT

47.2 x

EV/CFO

20.7 x

EV/FCF

14.4 x

Revenue/Employee

207.4 k

Debt/Equity

0.3 x

Debt/Assets

0.2 x

Financial Leverage

1.9 x

Baxter International Market Value History

Baxter International Online and Social Media Presence

Baxter International News and Updates

Baxter International Company Life and Culture

You may also be interested in